Lipocine Doses First Patient in Phase 3 LPCN 1154 Trial
June 26, 2025
Phase 3 Top Line Results Expected Q2 2026 Lipocine Inc, a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral